非酒精性脂肪性肝病无创性检查的混杂因素。
Confounding factors of non-invasive tests for nonalcoholic fatty liver disease.
机构信息
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 9/F, Prince of Wales Hospital, 30-32 Ngan Shing Street, Hong Kong, China.
State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
出版信息
J Gastroenterol. 2020 Aug;55(8):731-741. doi: 10.1007/s00535-020-01686-8. Epub 2020 May 25.
Abstract
Nonalcoholic fatty liver disease (NAFLD) affects at least 25% of the general adult population worldwide. Because only a fraction of the patients would develop liver-related complications, it is preferable to perform non-invasive tests as the initial assessment. This review summarizes the known and potential confounding factors that affect the performance of non-invasive tests of hepatic steatosis and fibrosis in patients with NAFLD. Clinicians may apply the knowledge and exercise caution in selecting investigations and interpreting test results when confounding factors are present.
摘要
非酒精性脂肪性肝病（NAFLD）影响着全球至少 25%的普通成年人群。由于只有一部分患者会发展为与肝脏相关的并发症，因此最好进行非侵入性检查作为初始评估。这篇综述总结了已知和潜在的混杂因素，这些因素会影响 NAFLD 患者肝脂肪变性和纤维化的非侵入性检查的性能。当存在混杂因素时，临床医生可以应用这些知识并谨慎选择检查和解释检查结果。
相似文献
1
Confounding factors of non-invasive tests for nonalcoholic fatty liver disease.
J Gastroenterol. 2020 Aug;55(8):731-741. doi: 10.1007/s00535-020-01686-8. Epub 2020 May 25.
2
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
Clin Liver Dis. 2018 Feb;22(1):73-92. doi: 10.1016/j.cld.2017.08.004.
3
Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
Obes Surg. 2017 Sep;27(9):2347-2353. doi: 10.1007/s11695-017-2606-9.
4
Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.
Obes Rev. 2018 Feb;19(2):281-294. doi: 10.1111/obr.12628. Epub 2017 Nov 9.
5
Liver fibrosis markers of nonalcoholic steatohepatitis.
World J Gastroenterol. 2015 Jun 28;21(24):7427-35. doi: 10.3748/wjg.v21.i24.7427.
6
Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
Hormones (Athens). 2014 Oct-Dec;13(4):519-31. doi: 10.14310/horm.2002.1493. Epub 2014 Nov 5.
7
Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
Dig Dis Sci. 2016 May;61(5):1356-64. doi: 10.1007/s10620-016-4079-4. Epub 2016 Mar 26.
8
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments.
Clin Mol Hepatol. 2023 Feb;29(Suppl):S150-S156. doi: 10.3350/cmh.2022.0362. Epub 2023 Jan 25.
9
Nonalcoholic fatty liver disease: a systematic review.
JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370.
10
Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
Liver Int. 2018 Feb;38(2):331-341. doi: 10.1111/liv.13549. Epub 2017 Sep 5.
引用本文的文献
1
Non-alcoholic fatty liver disease (NAFLD) and its association to cardiovascular disease: A comprehensive meta-analysis.
JRSM Cardiovasc Dis. 2025 Mar 21;14:20480040251325929. doi: 10.1177/20480040251325929. eCollection 2025 Jan-Dec.
2
Multi-site, multi-vendor development and validation of a deep learning model for liver stiffness prediction using abdominal biparametric MRI.
Eur Radiol. 2025 Jan 9. doi: 10.1007/s00330-024-11312-3.
3
Metabolic dysfunction-associated steatotic liver disease and gallbladder polyp development: an observational study.
Sci Rep. 2024 Sep 28;14(1):22446. doi: 10.1038/s41598-024-73429-1.
4
MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD.
Hepatol Int. 2024 Oct;18(Suppl 2):909-921. doi: 10.1007/s12072-024-10661-x. Epub 2024 Jun 24.
5
The Application of Artificial Intelligence (AI)-Based Ultrasound for the Diagnosis of Fatty Liver Disease: A Systematic Review.
Cureus. 2023 Dec 15;15(12):e50601. doi: 10.7759/cureus.50601. eCollection 2023 Dec.
6
Association between novel inflammatory markers and non-alcoholic fatty liver disease: a cross-sectional study.
Eur J Gastroenterol Hepatol. 2024 Feb 1;36(2):203-209. doi: 10.1097/MEG.0000000000002686. Epub 2023 Dec 1.
7
Hepatic Impairment as a Risk Factor for Drug Safety: Suitability and Comparison of Four Liver Scores as Screening Tools.
J Clin Med. 2023 Oct 27;12(21):6814. doi: 10.3390/jcm12216814.
8
Hepatic Involvement across the Metabolic Syndrome Spectrum: Non-Invasive Assessment and Risk Prediction Using Machine Learning.
J Clin Med. 2023 Aug 30;12(17):5657. doi: 10.3390/jcm12175657.
9
Liver Fat Scores for Noninvasive Diagnosis and Monitoring of Nonalcoholic Fatty Liver Disease in Epidemiological and Clinical Studies.
J Clin Transl Hepatol. 2023 Oct 28;11(5):1212-1227. doi: 10.14218/JCTH.2022.00019. Epub 2023 May 31.
10
Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease.
Int J Mol Sci. 2023 Feb 2;24(3):2844. doi: 10.3390/ijms24032844.
本文引用的文献
1
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Gastroenterology. 2020 May;158(6):1611-1625.e12. doi: 10.1053/j.gastro.2020.01.043. Epub 2020 Feb 4.
2
Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease.
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2073-2080.e7. doi: 10.1016/j.cgh.2020.01.020. Epub 2020 Jan 23.
3
Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
Hepatology. 2020 Oct;72(4):1219-1229. doi: 10.1002/hep.31121. Epub 2020 Oct 9.
4
Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1842-1850.e6. doi: 10.1016/j.cgh.2019.11.060. Epub 2019 Dec 13.
5
Predicting NASH response with liver fat: Are we back to square one?
J Hepatol. 2020 Mar;72(3):386-388. doi: 10.1016/j.jhep.2019.10.024. Epub 2019 Dec 6.
6
Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease.
Liver Int. 2020 Mar;40(3):581-589. doi: 10.1111/liv.14301. Epub 2019 Dec 8.
7
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11.
8
Application of transient elastography in nonalcoholic fatty liver disease.
Clin Mol Hepatol. 2020 Apr;26(2):128-141. doi: 10.3350/cmh.2019.0001n. Epub 2019 Nov 8.
9
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
J Hepatol. 2020 Mar;72(3):401-410. doi: 10.1016/j.jhep.2019.09.018. Epub 2019 Oct 4.
10
Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease.
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2843-2845.e2. doi: 10.1016/j.cgh.2019.09.027. Epub 2019 Sep 28.
Zotero 插件